Abstracts tagged "Biomarkers"

Abstract Number: 2858 • 2017 ACR/ARHP Annual Meeting
Validation of Biomarkers to Predict Flare in Polyarticular JIA upon Stopping Anti-TNF Therapy
Daniel J Lovell¹, Sarah Ringold² and P. Scott Eastman³, ¹PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Seattle Children's Hospital, Seattle, WA, ³Senior Director, New Product Development, Crescendo Bioscience, South San Francisco, CA
Background/Purpose: More than 40% of children with polyarticular forms of Juvenile Idiopathic Arthritis (JIA) experience clinical inactive disease on medication (CR). No clinical variable or…
Abstract Number: 78 • 2017 ACR/ARHP Annual Meeting
IL-37 Is Associated with Increased Atherogenesis in Patients with Rheumatoid Arthritis
Barbora Sumova^1,2, Tereza Lennerova^1,2, Lucie Andres Cerezo¹, Hana Hulejova¹, Romana Jandova¹, Karel Pavelka^1,2, Jiri Vencovsky^1,2 and Ladislav Senolt^1,2, ¹Institute of Rheumatology, Prague, Czech Republic, Prague, Czech Republic, ²Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Interleukin-37 (IL-37) is one of few anti-inflammatory cytokines belonging to the IL-1 cytokine family. It is mainly produced by immune cells of innate immunity…
Abstract Number: 674 • 2017 ACR/ARHP Annual Meeting
Identification of IRAK4-Dependent Gene Signature As a Biomarker Candidate for IRAK4 Small-Molecule Inhibitor in Systemic Lupus Erythematosus
A. Francesca Setiadi¹, Kate Senger¹, Jason Hackney², Neta Zuckerman¹, Swathi Sujatha-Bhaskar¹, George Francis¹, Marian Bryan¹, Hans Brightbill¹, Ali A. Zarrin¹ and Michael J. Townsend¹, ¹Genentech, South San Francisco, CA, ²Bioinformatics and Computational Biology, Genentech, South San Francisco, CA
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a heterogeneous disease. Interleukin-1 receptor-associated kinase 4 (IRAK4) activity is predicted to affect multiple pathogenic pathways in SLE1. We…
Abstract Number: 940 • 2017 ACR/ARHP Annual Meeting
IL1RN Variation Is Associated with Systemic Juvenile Idiopathic Arthritis and Predicts Non-Response to Anakinra Treatment
Emily Shuldiner¹, Victoria Arthur¹, Anne Hinks², Patricia Woo³, Wendy Thomson², Elaine F. Remmers⁴ and Michael J. Ombrello¹, ¹Translational Genetics and Genomics Unit, NIAMS, NIH, Bethesda, MD, ²Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, United Kingdom, ³University College London, London, United Kingdom, ⁴Genetics and Genomics Branch, NIH, NIAMS, Bethesda, MD
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is a childhood inflammatory disease whose pathophysiology is poorly understood. sJIA is phenotypically heterogeneous with variable manifestations and responses…
Abstract Number: 1416 • 2017 ACR/ARHP Annual Meeting
Higher Expression of Type 1 Interferon in Synovitis of Patient with Undifferentiated Arthritis before They Met Rheumatoid Arthritis Criteria Compared to Established Rheumatoid Arthritis. a Retrospective Study with 14 Years of Follow-up
Andrea Cuervo¹, Raquel Celis², Julio Ramírez³, Alicia Usategui⁴, Regina Faré⁵, M. Victoria Hernández⁶, Virginia Ruiz-Esquide³, Jose Inciarte-Mundo⁷, Raimon Sanmarti⁸, Jose L. Pablos⁹ and Juan D. Cañete⁷, ¹Arthritis Unit. Rheumatology Dpt, Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona and IDIBAPS, Barcelona, Spain, ²Arthritis Unit, Rheumatology Department, Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona and IDIBAPS, Barcelona, Spain, ³Rheumatology Service, Hospital Clínic de Barcelona, Barcelona, Spain, ⁴Grupo de Enfermedades Inflamatorias y Autoinmunes, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain, ⁵Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain, ⁶Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ⁷Rheumatology Department, Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona, Barcelona, Spain, ⁸Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona, Barcelona, Spain, ⁹Servicio de Reumatología, Hospital 12 de Octubre, Madrid, Spain
Background/Purpose: Undifferentiated Arthritis (UA) is defined as an inflammatory oligo/poly arthritis that does not fulfil criteria for a definitive diagnosis.Delay in diagnosis and treatment leads…
Abstract Number: 2176 • 2017 ACR/ARHP Annual Meeting
Clusterin Is Upregulated in Muscle Tissue and Serum in Idiopathic Inflammatory Myopathies and Is Associated with Clinical Disease Activity
Tereza Lennerova^1,2, Lucia Vernerova¹, Martin Klein¹, Veronika Hruskova^1,3, Lucie Andres Cerezo¹, Barbora Sumova^1,2, Michal Tomcik^1,2, Sabina Oreska^1,2, Herman F Mann^1,2, Josef Zamecnik⁴, Karel Pavelka^1,2, Jiri Vencovsky^1,2 and Ladislav Senolt^1,2, ¹Institute of Rheumatology, Prague, Czech Republic, Prague, Czech Republic, ²Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ³Faculty of Science, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁴Department of Pathology and Molecular Medicine, 2nd Medical School and University Hospital Motol, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Clusterin (also known as apolipoprotein J) is a molecular chaperone that participates in a number of biological processes, such as inflammation and apoptosis. Recent…
Abstract Number: 2863 • 2017 ACR/ARHP Annual Meeting
Serum Proteomic Signatures Predict Relapse in Rheumatoid Arthritis Patients Undergoing DMARD Withdrawal
Liam O'Neil¹, Victor Spicer², Carol A Hitchon², Juergen Rech³, Axel J. Hueber⁴, John Wilkins², Hani El-Gabalawy¹ and Georg Schett³, ¹Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ²University of Manitoba, Winnipeg, MB, Canada, ³Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Erlangen, Germany., Erlangen, Germany, ⁴Department of Medicine 3, Rheumatology and Immunology, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: Early and targeted treatment strategies have led to increasing numbers of patients with RA achieving sustained clinical remission. If and when to taper Disease…
Abstract Number: 129 • 2017 ACR/ARHP Annual Meeting
Impact of the Multi-Biomarker Disease Activity Score Results on Whether Rheumatologists Changed Biologic Therapy for RA Patients
Jeffrey R. Curtis¹, Kerri Ford², Lang Chen³, Huifeng Yun³ and Fenglong Xie⁴, ¹Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ²Crescendo Bioscience Inc., South San Francisco, CA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The multi-biomarker disease activity (MBDA) score is a validated test used to assess disease activity for patients with rheumatoid arthritis (RA). How it is…
Abstract Number: 675 • 2017 ACR/ARHP Annual Meeting
Tissue-Based Biomarkers in Cutaneous Lupus Erythematosus: Type I IFN Responsive Protein Mxa and a Marker for Lymphocytic Inflammation (CD45) Correlate with CLASI Cross-Sectionally and Longitudinally
Taylor L. Reynolds¹, Carrie Wager¹, Stefan Hamann¹, Xueli Zhang¹, Galina Marsh¹, Cristina Musselli¹, Nathalie Franchimont¹, Agnes Gardet¹, Robert Dunstan², Dania Rabah¹ and Victoria P Werth³, ¹Biogen, Cambridge, MA, ²Abbvie, Worcester, MA, ³University of Pennsylvania and the VA Medical Center, Philadelphia, PA
Background/Purpose: Cutaneous lupus erythematosus (CLE) is the cutaneous manifestation of SLE, affecting 85% of patients1. CLE is subdivided into acute, subacute and chronic/discoid forms. Discoid…
Abstract Number: 969 • 2017 ACR/ARHP Annual Meeting
Modulation of Cartilage Degradation Biomarkers Reflect the Activation and Inhibition of Pro-Inflammatory Cytokine Signaling in an Ex Vivo Model of Bovine Cartilage
Cecilie F. Kjelgaard-Petersen^1,2, Neha Sharma^1,3, Ashref Kayed^4,5, Britt Christensen¹, Morten Karsdal⁶, Anne-C. Bay-Jensen⁷ and Christian S. Thudium¹, ¹Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ²Bioengineering, Technical University of Denmark, Kgs. Lyngby, Denmark, ³Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark, ⁴Research and Biomarkers, Nordic Bioscience, Herlev, Denmark, ⁵Biomolecular Sciences, University of Copenhagen, Copenhagen, Denmark, ⁶Biomarkers and Reseacrh, Nordic Bioscience, Herlev, Denmark, ⁷Biomarkers and Reseach, Nordic Bioscience, Herlev, Denmark
Background/Purpose: Several inflammatory cytokines and intracellular signaling pathways have been targeted in drug development with varying clinical results. Improved understanding of the intracellular signaling’s modulation…
Abstract Number: 1441 • 2017 ACR/ARHP Annual Meeting
Evaluation of Ultrasound-Detecting Efficacy of Abatacept By Profiling Multiple Serum Cytokines, Chemokines and Bone-Related Biomarkers in Rheumatoid Arthritis Patients: Kyushu Multicenter Rheumatoid Arthritis Ultrasound Prospective Observational Cohort Study
Shinya Kawashiri^1,2,3, Ayako Nishino^3,4, Nobutaka Eiraku³, Tamami Yoshitama³, Naoki Matsuoka³, Toshiyuki Aramaki³, Yukitaka Ueki³, Akitomo Okada³, Hiroaki Hamada³, Shuji Nagano³, Keita Fujikawa³ and Atsushi Kawakami^1,3, ¹Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Departments of Community Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ³Kyushu multicenter rheumatoid arthritis ultrasound prospective observational cohort study group, Nagasaki, Japan, ⁴Center for Comprehensive Community Care Education, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
Background/Purpose: We have been prospectively investigating therapeutic efficacy of biologic or targeted synthetic DMARDs in patients with rheumatoid arthritis (RA) by ultrasound (US) in Kyushu…
Abstract Number: 2198 • 2017 ACR/ARHP Annual Meeting
Combinatorial Peripheral Blood Inflammatory and MRI-Based Biomarkers Predict Radiographic Joint Space Narrowing in Knee OA
Svetlana Krasnokutsky Samuels¹, Hua Zhou², Mukundan Attur¹, Jonathan Samuels¹, Gregory Chang³, Jenny Bencardino⁴, Sisi Ma², Leon Rybak³ and Steven B. Abramson⁵, ¹Rheumatology, NYU Langone Medical Center, New York, NY, ²Bioinformatics, New York University, New York, NY, ³Department of Radiology, NYU Langone Medical Center, New York, NY, ⁴Radiology, NYU Langone Medical Center, New York, NY, ⁵Dept of Medicine, NYU Langone Medical Center, New York, NY
Background/Purpose: Inflammation contributes to OA disease pathogenesis. Subsets of knee OA patients with peripheral blood leukocyte (PBL) detected inflammatory gene expression profiles exhibit more rapid…
Abstract Number: 2864 • 2017 ACR/ARHP Annual Meeting
Anti-Acetylated Peptide Antibodies Positive Rheumatoid Arthritis Patients Show a More Favorable Response to Tumor-Necrosis-Factor Inhibitor Treatment and Better Disease Activity Control over Time
Paul Studenic¹, Stephan Blüml¹, Holger Bang², Daniela Sieghart¹, Daniel Aletaha¹, Helmuth Haslacher³, Josef S. Smolen^1,4 and Günter Steiner¹, ¹Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria, ²Orgentec Diagnostika GmbH, Mainz, Germany, ³Medical University Vienna, Department of Laboratory Medicine, Vienna, Austria, ⁴Department of Internal Medicine, Hietzing Hospital, Vienna, Austria
Background/Purpose: Anti-acetylated-peptide antibodies (AAPA) have been found in rheumatoid arthritis (RA) patients and may be additional markers for diagnosis, particularly in rheumatoid factor (RF)/ anti-citrullinated…
Abstract Number: 138 • 2017 ACR/ARHP Annual Meeting
Prediction of Cardiovascular Events in Rheumatoid Arthritis Patients Using a Multi-Biomarker of Disease Activity
Fenglong Xie¹, Lang Chen², Huifeng Yun² and Jeffrey R. Curtis³, ¹Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The ACC/AHA recommends preventive strategies for patients with a high predicted risk of atherosclerotic cardiovascular disease (CVD). RA patients are at higher risk for…
Abstract Number: 679 • 2017 ACR/ARHP Annual Meeting
Distinct Interferon Scores Are Separately Associated with Activity and Long Term Sequelae in SLE
Katherine Dutton¹, Antonios Psarras², Md Yuzaiful Md Yusof², Paul Emery³, Yasser M El-Sherbiny⁴ and Edward M Vital¹, ¹University of Leeds, Leeds, United Kingdom, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁴NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals, NHS Trust, Leeds, United Kingdom
Background/Purpose: Type I interferon (IFN-I) has a crucial role in the pathogenesis and activity of Systemic Lupus Erythematosis (SLE). IFN-I targeted therapies are currently in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].